XTANT MEDICAL (Germany) Analysis
XMS Stock | EUR 0.53 0.04 8.16% |
XTANT MEDICAL HLDGS is overvalued with Real Value of 0.43 and Hype Value of 0.53. The main objective of XTANT MEDICAL stock analysis is to determine its intrinsic value, which is an estimate of what XTANT MEDICAL HLDGS is worth, separate from its market price. There are two main types of XTANT MEDICAL's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect XTANT MEDICAL's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of XTANT MEDICAL's stock to identify patterns and trends that may indicate its future price movements.
The XTANT MEDICAL stock is traded in Germany on Frankfurt Exchange, with the market opening at 08:00:00 and closing at 22:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Germany. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and XTANT MEDICAL's ongoing operational relationships across important fundamental and technical indicators.
XTANT |
XTANT Stock Analysis Notes
About 75.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.08. XTANT MEDICAL HLDGS had not issued any dividends in recent years. Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. XTANT MEDICAL operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 110 people. For more information please call the company at 406 388 0480 or visit http://www.xtantmedical.com.XTANT MEDICAL HLDGS Investment Alerts
XTANT MEDICAL HLDGS has some characteristics of a very speculative penny stock | |
XTANT MEDICAL HLDGS appears to be risky and price may revert if volatility continues | |
The company reported the revenue of 56.67 M. Net Loss for the year was (2.83 M) with profit before overhead, payroll, taxes, and interest of 32.49 M. | |
Over 75.0% of the company outstanding shares are owned by institutional investors |
XTANT MEDICAL Thematic Classifications
In addition to having XTANT MEDICAL stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
![]() | DrugsDrug manufacturing and delivery |
XTANT Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 72.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate XTANT MEDICAL's market, we take the total number of its shares issued and multiply it by XTANT MEDICAL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.XTANT Profitablity
XTANT MEDICAL's profitability indicators refer to fundamental financial ratios that showcase XTANT MEDICAL's ability to generate income relative to its revenue or operating costs. If, let's say, XTANT MEDICAL is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, XTANT MEDICAL's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of XTANT MEDICAL's profitability requires more research than a typical breakdown of XTANT MEDICAL's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.15) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.1. Technical Drivers
As of the 19th of July, XTANT MEDICAL owns the Mean Deviation of 3.93, market risk adjusted performance of (2.96), and Standard Deviation of 5.15. In relation to fundamental indicators, the technical analysis model lets you check practical technical drivers of XTANT MEDICAL HLDGS, as well as the relationship between them. Please check out XTANT MEDICAL HLDGS information ratio, value at risk, and the relationship between the standard deviation and treynor ratio to decide if XTANT MEDICAL HLDGS is priced some-what accurately, providing market reflects its prevailing price of 0.53 per share.XTANT MEDICAL HLDGS Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of XTANT MEDICAL for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out XTANT MEDICAL HLDGS short-term fluctuations and highlight longer-term trends or cycles.
XTANT MEDICAL Outstanding Bonds
XTANT MEDICAL issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. XTANT MEDICAL HLDGS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XTANT bonds can be classified according to their maturity, which is the date when XTANT MEDICAL HLDGS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
XEROX HLDGS P Corp BondUS98421MAB28 | View | |
XEROX HLDGS P Corp BondUS98421MAA45 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
US98420EAB11 Corp BondUS98420EAB11 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
XTANT MEDICAL Predictive Daily Indicators
XTANT MEDICAL intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of XTANT MEDICAL stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Daily Balance Of Power | 9.2 T | |||
Rate Of Daily Change | 1.08 | |||
Day Median Price | 0.53 | |||
Day Typical Price | 0.53 | |||
Price Action Indicator | 0.02 | |||
Period Momentum Indicator | 0.04 | |||
Relative Strength Index | 59.0 |
XTANT MEDICAL Forecast Models
XTANT MEDICAL's time-series forecasting models are one of many XTANT MEDICAL's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary XTANT MEDICAL's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About XTANT Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how XTANT MEDICAL prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling XTANT shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as XTANT MEDICAL. By using and applying XTANT Stock analysis, traders can create a robust methodology for identifying XTANT entry and exit points for their positions.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. XTANT MEDICAL operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 110 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding XTANT MEDICAL to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
All Next | Launch Module |
Complementary Tools for XTANT Stock analysis
When running XTANT MEDICAL's price analysis, check to measure XTANT MEDICAL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTANT MEDICAL is operating at the current time. Most of XTANT MEDICAL's value examination focuses on studying past and present price action to predict the probability of XTANT MEDICAL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTANT MEDICAL's price. Additionally, you may evaluate how the addition of XTANT MEDICAL to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |